FDA looks to strength­en ex­pand­ed ac­cess pro­gram

The FDA on Thurs­day un­veiled plans to fur­ther strength­en its ex­pand­ed ac­cess pro­gram, as the con­tro­ver­sial Right to Try leg­is­la­tion has yet to help any pa­tients.

The ex­pand­ed ac­cess pro­gram al­lows pa­tients with se­ri­ous or im­me­di­ate­ly life-threat­en­ing dis­eases who are un­able to par­tic­i­pate in clin­i­cal tri­als to gain ac­cess to promis­ing in­ves­ti­ga­tion­al treat­ments.

Over the last five years, the FDA has au­tho­rized more than 9,000 ap­pli­ca­tions across drugs, bi­o­log­ics and de­vices through the agency’s ex­pand­ed ac­cess pro­gram, and the agency ex­pects about 800 more in­di­vid­ual re­quests next year. About 99% of all the re­quests the FDA has re­ceived, across all ap­pli­ca­tion types, have been grant­ed, though those re­quests are grant­ed af­ter the com­pa­ny of­fer­ing the treat­ment al­so signs off on the re­quest.

Fol­low­ing an in­de­pen­dent as­sess­ment of the ex­pand­ed ac­cess pro­gram last year, the agency says that it has now agreed to up­date the FDA’s Ex­pand­ed Ac­cess web­pages to im­prove us­abil­i­ty through the stream­lin­ing of con­tent and a more user-friend­ly or­ga­ni­za­tion. “This in­cludes a re­duc­tion in du­pli­ca­tion, as well as the ad­di­tion of new pages with com­mon­ly re­quest­ed in­for­ma­tion, such as forms and key­words,” the FDA said.

And as part of the re­cent­ly an­nounced pro­posed re­or­ga­ni­za­tion of the Of­fice of the Com­mis­sion­er, the FDA al­so in­tends to for­mal­ly es­tab­lish an agency-wide Pa­tient Af­fairs Staff and Health Care Provider Af­fairs Pro­gram, un­der the over­sight of the Of­fice of Clin­i­cal Pol­i­cy and Pro­grams.

“This will en­hance our en­gage­ment with these im­por­tant ex­ter­nal stake­hold­er groups. The Pa­tient Af­fairs Staff is al­ready in place and charged with serv­ing as the ‘home base’ and pri­ma­ry point of en­try for pa­tients and physi­cians start­ing the EA process and nav­i­gat­ing them through the steps,” the FDA said.

Mean­while, the FDA has es­tab­lished an agency-wide Ex­pand­ed Ac­cess Co­or­di­nat­ing Com­mit­tee, which fa­cil­i­tates cross-cen­ter com­mu­ni­ca­tion and pro­motes dis­cus­sion to ad­dress cross-cut­ting is­sues re­lat­ed to ex­pand­ed ac­cess to pro­mote con­sis­ten­cy and best prac­tices.

Right to Try

Mean­while, the FDA has re­leased a new web­site to help pa­tients un­der­stand Right to Try, and the agency has es­tab­lished a work group to con­sid­er what steps may be re­quired to im­ple­ment this leg­is­la­tion in a way that ad­vances Con­gress’ in­tent to pro­mote ac­cess and pro­tect pa­tients.

But such im­ple­men­ta­tion ef­forts from the FDA have al­ready proven con­tro­ver­sial, as Sen. Ron John­son (R-WI) made clear that the law “in­tends to di­min­ish the FDA’s pow­er over peo­ple’s lives.

Fo­cus reached out to two com­pa­nies ad­ver­tis­ing the use of Right to Try – Stem­Vacs and Ther­a­peu­tic So­lu­tions In­ter­na­tion­al – though nei­ther re­spond­ed.

A re­cent ar­ti­cle in Health Af­fairs on Right to Try not­ed, “In a way, pa­tients may have ben­e­fit­ed from RTT af­ter all: not be­cause it cre­at­ed a new path­way that cut the FDA out of the pic­ture, but be­cause it raised aware­ness that non-tri­al ac­cess was pos­si­ble, thus gal­va­niz­ing pa­tients and their doc­tors to re­quest it.”


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

Norbert Bischofberger. Kronos

Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

A little over a year ago when I reported on Norbert Bischofberger’s jump from the CSO job at giant Gilead to a tiny upstart called Kronos, I noted that with his connections in biotech finance, that $18 million launch round he was starting off with could just as easily have been $100 million or more.

With his first anniversary now behind him, Bischofberger has that mega-round in the bank.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Chas­ing Roche's ag­ing block­buster fran­chise, Am­gen/Al­ler­gan roll out Avastin, Her­ceptin knock­offs at dis­count

Let the long battle for biosimilars in the cancer space begin.

Amgen has launched its Avastin and Herceptin copycats — licensed from the predecessors of Allergan — almost two years after the FDA had stamped its approval on Mvasi (bevacizumab-awwb) and three months after the Kanjinti OK (trastuzumab-anns). While the biotech had been fielding biosimilars in Europe, this marks their first foray in the US — and the first oncology biosimilars in the country.

Seer adds ex-FDA chief Mark Mc­Clel­lan to the board; Her­cules Cap­i­tal makes it of­fi­cial for new CEO Scott Bluestein

→ On the same day it announced a $17.5 million Series C, life sciences and health data company Seer unveiled that it had lured former FDA commissioner and ex-CMS administrator Mark McClellan on to its board. “Mark’s deep understanding of the health care ecosystem and visionary insights on policy reform will be crucial in informing our thinking as we work to bring our liquid biopsy and life sciences products to market,” said Seer chief and founder Omid Farokhzad in a statement.

Daniel O'Day

No­var­tis hands off 3 pre­clin­i­cal pro­grams to the an­tivi­ral R&D mas­ters at Gilead

Gilead CEO Daniel O’Day’s new task hunting up a CSO for the company isn’t stopping the industry’s dominant antiviral player from doing pipeline deals.

The big biotech today snapped up 3 preclinical antiviral programs from pharma giant Novartis, with drugs promising to treat human rhinovirus, influenza and herpes viruses. We don’t know what the upfront is, but the back end has $291 million in milestones baked in.

Vas Narasimhan, AP Images

On a hot streak, No­var­tis ex­ecs run the odds on their two most im­por­tant PhI­II read­outs. Which is 0.01% more like­ly to suc­ceed?

Novartis CEO Vas Narasimhan is living in the sweet spot right now.

The numbers are running a bit better than expected, the pipeline — which he assembled as development chief — is performing and the stock popped more than 4% on Thursday as the executive team ran through their assessment of Q2 performance.

Year-to-date the stock is up 28%, so the investors will be beaming. Anyone looking for chinks in their armor — and there are plenty giving it a shot — right now focus on payer acceptance of their $2.1 million gene therapy Zolgensma, where it’s early days. And CAR-T continues to underperform, but Novartis doesn’t appear to be suffering from it.

So what could go wrong?

Actually, not much. But Tim Anderson at Wolfe pressed Narasimhan and his development chief John Tsai to pick which of two looming Phase III readouts with blockbuster implication had the better odds of success.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M up­front

Boehringer Ingelheim’s BD team is on a global deal spree. The German pharma company just wrapped its third deal in 3 weeks, going back to Korea for its latest pipeline pact — this time focused on idiopathic pulmonary fibrosis.

They’re handing over $50 million to get their hands on BBT-877, an ATX inhibitor from Korea’s Bridge Biotherapeutics that was on display at a science conference in Dallas recently. There’s not a whole lot of data to evaluate the prospects here.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Servi­er scoots out of an­oth­er col­lab­o­ra­tion with Macro­Gen­ics, writ­ing off their $40M

Servier is walking out on a partnership with MacroGenics $MGNX — for the second time.

After the market closed on Wednesday MacroGenics put out word that Servier is severing a deal — inked close to 7 years ago — to collaborate on the development of flotetuzumab and other Dual-Affinity Re-Targeting (DART) drugs in its pipeline.

MacroGenics CEO Scott Koenig shrugged off the departure of Servier, which paid $20 million to kick off the alliance and $20 million to option flotetuzumab — putting a heavily back-ended $1 billion-plus in additional biobuck money on the table for the anti-CD123/CD3 bispecific and its companion therapies.